Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics Limited has issued an addendum to its 2025 Annual General Meeting notice to include a new resolution for the appointment of BDO Audit Pty Ltd as the company’s auditor. This resolution, initially mentioned in a January announcement, was omitted from the original notice. The AGM will proceed as scheduled without changes to its date, time, or venue. This update ensures compliance and transparency in the company’s governance, potentially impacting stakeholder confidence positively.
More about Tryptamine Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing novel formulations of psilocin for use in psychotherapy to treat diseases with unmet medical needs. The company’s lead program, TRP-8803, aims to improve the administration of psilocin, potentially enhancing its efficacy and safety. Tryp has completed Phase 2a clinical trials for binge eating disorder and fibromyalgia and is conducting trials for irritable bowel syndrome.
Average Trading Volume: 2,095,577
Technical Sentiment Signal: Buy
Current Market Cap: A$54.72M
For an in-depth examination of TYP stock, go to TipRanks’ Overview page.